10.6084/m9.figshare.5124178.v1
Savelli G.
Savelli
G.
Zaniboni A.
Zaniboni
A.
Bertagna F.
Bertagna
F.
Bosio G.
Bosio
G.
Nisa L.
Nisa
L.
Rodella C.
Rodella
C.
Biasiotto G.
Biasiotto
G.
Bettinsoli G.
Bettinsoli
G.
Migliorati E.
Migliorati
E.
Peli A.
Peli
A.
Supplementary Material for: Peptide Receptor Radionuclide Therapy (PRRT) in a Patient Affected by Metastatic Breast Cancer with Neuroendocrine Differentiation
Karger Publishers
2012
Radionuclide therapy
Peptide receptors
2012-10-22 00:00:00
Dataset
https://karger.figshare.com/articles/dataset/Supplementary_Material_for_Peptide_Receptor_Radionuclide_Therapy_PRRT_in_a_Patient_Affected_by_Metastatic_Breast_Cancer_with_Neuroendocrine_Differentiation/5124178
<b><i>Background: </i></b>Breast cancer (BC) is the most frequent cancer in European women with nearly 30% of the patients eventually developing metastases. Neuroendocrine differentiation is a rare event, but overexpression of somatostatin receptors in BC has been reported in many studies. <b><i>Case Report: </i></b>A patient with liver metastases from BC was treated with peptide receptor radionuclide therapy (PRRT). Computed tomography scan and biochemical examinations showed a clear response to radionuclide therapy. <b><i>Conclusion: </i></b>PRRT may be useful in metastatic BC patients.